KR102866133B1 - 트랜스-스플라이싱 분자 - Google Patents

트랜스-스플라이싱 분자

Info

Publication number
KR102866133B1
KR102866133B1 KR1020207032936A KR20207032936A KR102866133B1 KR 102866133 B1 KR102866133 B1 KR 102866133B1 KR 1020207032936 A KR1020207032936 A KR 1020207032936A KR 20207032936 A KR20207032936 A KR 20207032936A KR 102866133 B1 KR102866133 B1 KR 102866133B1
Authority
KR
South Korea
Prior art keywords
nucleotides
abca4
trans
intron
exons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207032936A
Other languages
English (en)
Korean (ko)
Other versions
KR20210018222A (ko
Inventor
필립 알. 존슨
브루스 씨. 슈넵
진 베넷
스콧 제이. 둘리
크리쉬나 자와할랄 피셔
준웨이 선
Original Assignee
더 트러스티스 오브 더 유니버시티 오브 펜실바니아
아시디엔 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 트러스티스 오브 더 유니버시티 오브 펜실바니아, 아시디엔 테라퓨틱스, 인크. filed Critical 더 트러스티스 오브 더 유니버시티 오브 펜실바니아
Priority to KR1020257032132A priority Critical patent/KR20250150157A/ko
Publication of KR20210018222A publication Critical patent/KR20210018222A/ko
Application granted granted Critical
Publication of KR102866133B1 publication Critical patent/KR102866133B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/85—Fusion polypeptide containing an RNA binding domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
KR1020207032936A 2018-04-17 2019-04-17 트랜스-스플라이싱 분자 Active KR102866133B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257032132A KR20250150157A (ko) 2018-04-17 2019-04-17 트랜스-스플라이싱 분자

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862658658P 2018-04-17 2018-04-17
US201862658667P 2018-04-17 2018-04-17
US62/658,658 2018-04-17
US62/658,667 2018-04-17
PCT/US2019/027981 WO2019204514A1 (en) 2018-04-17 2019-04-17 Trans-splicing molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257032132A Division KR20250150157A (ko) 2018-04-17 2019-04-17 트랜스-스플라이싱 분자

Publications (2)

Publication Number Publication Date
KR20210018222A KR20210018222A (ko) 2021-02-17
KR102866133B1 true KR102866133B1 (ko) 2025-09-30

Family

ID=68239871

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207032936A Active KR102866133B1 (ko) 2018-04-17 2019-04-17 트랜스-스플라이싱 분자
KR1020257032132A Pending KR20250150157A (ko) 2018-04-17 2019-04-17 트랜스-스플라이싱 분자

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257032132A Pending KR20250150157A (ko) 2018-04-17 2019-04-17 트랜스-스플라이싱 분자

Country Status (11)

Country Link
US (2) US11993776B2 (enExample)
EP (1) EP3781213A4 (enExample)
JP (2) JP7561624B2 (enExample)
KR (2) KR102866133B1 (enExample)
CN (1) CN112449605A (enExample)
AU (1) AU2019255708A1 (enExample)
BR (1) BR112020021228A2 (enExample)
CA (1) CA3097004A1 (enExample)
IL (1) IL278019A (enExample)
MX (2) MX2020010959A (enExample)
WO (1) WO2019204514A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102866133B1 (ko) 2018-04-17 2025-09-30 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 트랜스-스플라이싱 분자
KR20220002910A (ko) * 2019-04-17 2022-01-07 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 효율적인 rna 트랜스-스플라이싱을 위한 삼중 나선 종결인자
EP4284335A1 (en) 2021-02-01 2023-12-06 RegenxBio Inc. Gene therapy for neuronal ceroid lipofuscinoses
JP2024533163A (ja) 2021-09-03 2024-09-12 タシト・セラピューティクス・インコーポレーテッド スプライソソーム構成要素のリクルートを介したｒｎａ編集
WO2023220742A2 (en) * 2022-05-13 2023-11-16 Ascidian Therapeutics, Inc. Abca4 trans-splicing molecules
WO2024011203A2 (en) * 2022-07-07 2024-01-11 Intergalactic Therapeutics, Inc. Ocular vectors and uses thereof
EP4594505A1 (en) * 2022-09-30 2025-08-06 Centre National de la Recherche Scientifique Therapy by trans-splicing of opa1 pre-messenger rnas for the treatment of diseases associated with opa1 gene mutations
AU2024223513A1 (en) * 2023-02-15 2025-09-18 Ascidian Therapeutics, Inc. Htt trans-splicing molecules
WO2025166360A1 (en) * 2024-02-03 2025-08-07 Duke University Compositions for and methods of engineering the transcriptome

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016139321A1 (en) 2015-03-03 2016-09-09 Fondazione Telethon Multiple vector system and uses thereof
WO2017087900A1 (en) * 2015-11-19 2017-05-26 The Trustees Of The University Of Pennsylvania Compositions and methods for correction of heritable ocular disease
WO2017106370A1 (en) 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Compositions and methods for treatment of eye diseases
US20170342414A1 (en) 2011-09-05 2017-11-30 Stichting Katholieke Universiteit Antisense oligonucleotides for the treatment of leber congenital amaurosis

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0883344B2 (en) 1995-12-15 2010-06-09 VIRxSYS Corporation Therapeutic molecules generated by trans-splicing
US6280978B1 (en) 1995-12-15 2001-08-28 Intronn Holdings, Llc Methods and compositions for use in spliceosome mediated RNA trans-splicing
AU735272B2 (en) 1996-10-04 2001-07-05 Intronn Llc Sample collection devices and methods using markers and the use of such markers as controls in sample validation, laboratory evaluation and/or accreditation
US6929907B2 (en) 1999-12-31 2005-08-16 North Carolina State University Methods and compositions for determining the purity of chemically synthesized nucleic acids
CA2452690C (en) 2001-06-29 2016-08-16 Veri-Q, Inc. Methods and compositions for determining the purity of and purifying chemically synthesized nucleic acids
JP2006505242A (ja) 2002-02-12 2006-02-16 イントロン，インコーポレーテッド スプライセオソームにより媒介されるｒｎａトランス−スプライシングにおいて使用するための方法および組成物
US7399753B2 (en) 2002-02-25 2008-07-15 Virxsys Corporation Trans-splicing mediated photodynamic therapy
EP1485397A4 (en) 2002-02-25 2005-05-25 Intronn Inc IMAGING OF GENE EXPRESSION MEDIATED BY TRANS-SPISSAGE
CA2488249A1 (en) 2002-06-05 2003-12-18 Intronn, Inc. Spliceosome mediated rna trans-splicing in stem cells
EP1521766B1 (en) 2002-06-05 2012-11-07 VIRxSYS Corporation SPLICEOSOME MEDIATED RNA i TRANS /i -SPLICING AND CORRECTION OF FACTOR VIII GENETIC DEFECTS USING SPLICEOSOME MEDIATED RNA TRANS SPLING
US20040018622A1 (en) 2002-07-17 2004-01-29 Mitchell Lloyd G. Spliceosome mediated RNA trans-splicing for correction of skin disorders
DE60333032D1 (de) 2002-10-23 2010-07-29 Virxsys Corp Screening-verfahren zur identifizierung wirksamer prä-trans-spleissmoleküle
WO2005070948A1 (en) 2004-01-23 2005-08-04 Intronn, Inc. Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated rna trans splicing
US20060177933A1 (en) 2004-01-23 2006-08-10 Madaiah Puttaraju Expression of apoA-1 and variants thereof using spliceosome mediated RNA trans-splicing
WO2006026611A2 (en) 2004-08-31 2006-03-09 Mitchell Lloyd G Reverse transcriptase mediated rna gene expression
US7943374B2 (en) 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
US20090214478A1 (en) 2008-02-21 2009-08-27 Alberto Auricchio Method of treating ocular diseases by gene therapy
US8236557B2 (en) 2008-05-28 2012-08-07 University Of Missouri-Columbia Hybrid-AAV vectors to deliver large gene expression cassette
EP2151248A1 (en) 2008-07-30 2010-02-10 Johann Bauer Improved pre-mRNA trans-splicing molecule (RTM) molecules and their uses
AU2013234376B2 (en) * 2008-10-22 2016-07-28 Acucela, Inc. Compounds for treating ophthalmic diseases and disorders
US8648053B2 (en) 2010-10-20 2014-02-11 Rosalind Franklin University Of Medicine And Science Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome
WO2012158757A1 (en) 2011-05-16 2012-11-22 The Trustees Of The University Of Pennsylvania Proviral plasmids for production of recombinant adeno-associated virus
CA2878171C (en) 2012-07-11 2021-04-27 The Trustees Of The University Of Pennsylvania Aav-mediated gene therapy for rpgr x-linked retinal degeneration
WO2014062801A1 (en) 2012-10-16 2014-04-24 Massachusetts Institute Of Technology Production of stable non-polyadenylated rnas
GB201219762D0 (en) 2012-11-02 2012-12-19 Bauer Johann A RNA trans-splicing molecule (RTM) for use in the treatment of cancer
US10266845B2 (en) 2013-02-08 2019-04-23 The Trustees Of The University Of Pennsylvania Enhanced AAV-mediated gene transfer for retinal therapies
US9567376B2 (en) 2013-02-08 2017-02-14 The Trustees Of The University Of Pennsylvania Enhanced AAV-mediated gene transfer for retinal therapies
US10494645B2 (en) 2013-04-18 2019-12-03 Fondazione Telethon Effective delivery of large genes by dual AAV vectors
WO2015009575A1 (en) 2013-07-16 2015-01-22 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of disorders related to cep290
EP3553176A1 (en) 2014-03-10 2019-10-16 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
JP6930910B2 (ja) 2014-07-09 2021-09-01 レクソジェン・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＬＥＸＯＧＥＮ ＧｍｂＨ Ｒｎａ転写産物バリアントを定量するための方法及び製品
TWI820034B (zh) 2017-07-31 2023-11-01 香港商映像生物有限公司 眼部疾病之細胞模式及用於眼部疾病的療法
US11795455B2 (en) 2017-07-31 2023-10-24 Massachusetts Institute Of Technology RNA cleavage-induced transcript stabilizer and uses thereof
KR102866133B1 (ko) 2018-04-17 2025-09-30 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 트랜스-스플라이싱 분자
KR20220002910A (ko) 2019-04-17 2022-01-07 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 효율적인 rna 트랜스-스플라이싱을 위한 삼중 나선 종결인자
WO2020214990A1 (en) 2019-04-17 2020-10-22 Ascidian Therapeutics, Inc. Abca4 cell line and methods of use
EP3962295A1 (en) 2019-05-01 2022-03-09 The Procter & Gamble Company Probiotic bacterial strains that produce short chain fatty acids and compositions comprising same
WO2023220742A2 (en) 2022-05-13 2023-11-16 Ascidian Therapeutics, Inc. Abca4 trans-splicing molecules

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170342414A1 (en) 2011-09-05 2017-11-30 Stichting Katholieke Universiteit Antisense oligonucleotides for the treatment of leber congenital amaurosis
WO2016139321A1 (en) 2015-03-03 2016-09-09 Fondazione Telethon Multiple vector system and uses thereof
WO2017087900A1 (en) * 2015-11-19 2017-05-26 The Trustees Of The University Of Pennsylvania Compositions and methods for correction of heritable ocular disease
WO2017106370A1 (en) 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Compositions and methods for treatment of eye diseases

Also Published As

Publication number Publication date
KR20250150157A (ko) 2025-10-17
EP3781213A1 (en) 2021-02-24
KR20210018222A (ko) 2021-02-17
JP7561624B2 (ja) 2024-10-04
JP2021520837A (ja) 2021-08-26
BR112020021228A2 (pt) 2021-03-02
AU2019255708A1 (en) 2020-11-26
MX2020010959A (es) 2021-01-15
US20240318186A1 (en) 2024-09-26
IL278019A (en) 2020-11-30
JP2024099770A (ja) 2024-07-25
CA3097004A1 (en) 2019-10-24
CN112449605A (zh) 2021-03-05
WO2019204514A1 (en) 2019-10-24
US20210155938A1 (en) 2021-05-27
MX2025007209A (es) 2025-07-01
US12442003B2 (en) 2025-10-14
EP3781213A4 (en) 2022-10-19
US11993776B2 (en) 2024-05-28

Similar Documents

Publication Publication Date Title
KR102866133B1 (ko) 트랜스-스플라이싱 분자
AU2019346655B2 (en) Frataxin expression constructs having engineered promoters and methods of use thereof
AU2018260998B2 (en) Modulatory polynucleotides
KR102606174B1 (ko) 트리플 가이드 서열을 지닌 crispr/cas9를 사용한 엑손 스키핑 변형을 위한 최적화된 전략
CN112368390B (zh) Cns变性的基因疗法
KR20230057487A (ko) 게놈 조정을 위한 방법 및 조성물
KR20230053735A (ko) 게놈의 조정을 위한 개선된 방법 및 조성물
KR20200126997A (ko) 인간 대상체에서의 비-노화-관련 청각 손상의 치료를 위한 조성물 및 방법
AU2019403015B2 (en) Nuclease-mediated repeat expansion
CN116685329B (zh) 核酸构建体及其用于治疗脊髓性肌肉萎缩症的用途
KR20230127221A (ko) Cag 반복 질환을 치료하기 위한 rna 표적화 조성물및 방법
KR20200056428A (ko) 변이체 RNAi
KR20210049833A (ko) Mma의 치료를 위한 비-붕괴적 유전자 요법
KR20200127170A (ko) Pah 유전자 기능 복원을 위한 아데노-연관 바이러스 조성물 및 이의 사용 방법
CN112639108A (zh) 治疗非综合征性感觉神经性听力损失的方法
KR20220097414A (ko) X-연관 연소 망막층간분리 치료법을 위한 crispr 및 aav 전략
KR20200095462A (ko) Hbb 유전자 기능 회복을 위한 아데노-연관 바이러스 조성물 및 이의 사용 방법
WO2020038473A1 (zh) 重组人ⅱ型线粒体动力蛋白样gtp酶基因序列及其应用
US20220395582A1 (en) Compositions and methods of inducing differentiation of a hair cell
KR20220155553A (ko) RNA-guided Nuclease를 이용한 LCA10 치료용 조성물 및 치료방법
CN114144203A (zh) 源于显性变异基因的疾患的治疗剂
WO2024069144A1 (en) Rna editing vector
KR20230041965A (ko) Slc26a4-연관 청력손실을 치료하기 위한 조성물 및 방법
RU2833486C1 (ru) Стратегии crispr и aav для терапии х-сцепленного ювенильного ретиношизиса
HK40040055A (en) Adeno-associated virus compositions for restoring pah gene function and methods of use thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601